Mineralys Therapeutics (MLYS) Short-term Investments (2022 - 2026)

Mineralys Therapeutics (MLYS) has 5 years of Short-term Investments data on file, last reported at $533.3 million in Q1 2026.

• For the quarter ending Q1 2026, Short-term Investments rose 199.61% year-over-year to $533.3 million; the trailing twelve-month figure through Mar 2026 stood at $533.3 million (up 199.61% YoY), and the FY2025 full-year result was $483.7 million, up 475.19% from the prior year.
• Short-term Investments advanced to $533.3 million in Q1 2026, from $483.7 million in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $533.3 million in Q1 2026 to a low of $22.4 million in Q4 2022.
• A 5-year average of $229.0 million and a median of $182.6 million in 2023 frame the typical range for Short-term Investments.
• Across the five-year window, Short-term Investments soared 735.66% in 2023 and tumbled 55.09% in 2024, its largest moves.
• Tracing MLYS's Short-term Investments over 5 years: stood at $22.4 million in 2022, then soared by 735.66% to $187.3 million in 2023, then plunged by 55.09% to $84.1 million in 2024, then soared by 475.19% to $483.7 million in 2025, then climbed by 10.25% to $533.3 million in 2026.
• Business Quant data shows MLYS's Short-term Investments at $533.3 million in Q1 2026, $483.7 million in Q4 2025, and $376.0 million in Q3 2025.